Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[The glitazones].

S Halimi1

  • 1Département d'urologie, néphrologie et endocrinologie, UF diabétologie 11 A, centre hospitalier universitaire de Grenoble, BP 217, 38043 Grenoble cedex 09, France. shalimi@chu-grenoble.fr <shalimi@chu-grenoble.fr>

La Revue De Medecine Interne
|January 11, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Glucose tolerance and cardiovascular risk biomarkers in non-diabetic non-obese obstructive sleep apnea patients: Effects of long-term continuous positive airway pressure.

Respiratory medicine·2016
Same author

Adverse effects and safety of SGLT-2 inhibitors.

Diabetes & metabolism·2015
Same author

Impact of flexible insulin therapy on blood glucose variability, oxidative stress and inflammation in type 1 diabetic patients: the VARIAFIT study.

Diabetes & metabolism·2014
Same author

Telemedicine and type 1 diabetes: is technology per se sufficient to improve glycaemic control?

Diabetes & metabolism·2013
Same author

Metabolic disturbances after acute vascular events: a comparative study of acute coronary syndrome and ischaemic atherothrombotic stroke.

Diabetes & metabolism·2012
Same author

WHO-5, a tool focusing on psychological needs in patients with diabetes: the French contribution to the DAWN study.

Diabetes & metabolism·2012
Same journal

[Cardiorespiratory functional disorders: A transnosologic approach].

La Revue de medecine interne·2026
Same journal

Heart involvements in systemic sclerosis beyond pulmonary hypertension: From conduction, rhythm and function defects to coronary artery disease.

La Revue de medecine interne·2026
Same journal

[Acute intermittent porphyria: When diagnostic errance jeopardizes patient health].

La Revue de medecine interne·2026
Same journal

Autosomal dominant polycystic kidney disease: Current perspectives in 2026.

La Revue de medecine interne·2026
Same journal

[Patient similarity: When the internist's reasoning meets artificial intelligence].

La Revue de medecine interne·2026
Same journal

[Satisfaction of healthcare professionals within a multidisciplinary day-hospitalization for patients with systemic autoimmune rare disease].

La Revue de medecine interne·2026
See all related articles

Glitazones, a new class of type 2 diabetes drugs, improve insulin sensitivity by targeting PPAR-gamma. They offer synergistic combinations for better glycemic control and may benefit cardiovascular health.

Area of Science:

  • Endocrinology
  • Pharmacology

Context:

  • Type 2 diabetes mellitus presents significant public health challenges, marked by microangiopathic complications and high cardiovascular risk.
  • Current treatments like metformin and sulfonylureas do not address underlying issues such as insulin resistance, lipotoxicity, and pancreatic beta-cell decline.

Purpose:

  • To introduce thiazolidine-diones (glitazones) as pharmacological ligands for peroxisome proliferator-activated receptor gamma (PPAR-gamma).
  • To elucidate the mechanism of glitazones in recruiting new adipocytes, reducing free fatty acids, and improving insulin resistance in muscle and liver.

Summary:

  • Glitazones activate PPAR-gamma, primarily in white adipose tissue, leading to adipocyte differentiation.
  • This process results in decreased free fatty acids and cytokines, ameliorating muscle and liver insulin resistance.

Related Experiment Videos

  • While the hypoglycemic effect is moderate, it is enhanced when combined with other oral antidiabetic drugs.

    • Impact:

    • Glitazones expand therapeutic options for type 2 diabetes, enabling novel synergistic treatment strategies.
    • Their PPAR-gamma agonism suggests potential applications in cancer, immunology, rheumatology, and infectious diseases.
    • Long-term studies are anticipated to validate benefits on beta-cell preservation and cardiovascular parameters in type 2 diabetes and metabolic syndrome.